Enterprise Value
819.1M
Cash
252.7M
Avg Qtr Burn
-28.18M
Short % of Float
12.76%
Insider Ownership
0.31%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Barzolvolimab (CDX-0159) Details Eosinophilic Esophagitis, Eosinophilic Gastritis | Phase 2 Data readout | |
Barzolvolimab (CDX-0159) (KIT receptor) Details KIT/Mast cell diseases | Phase 2 Update | |
Barzolvolimab (CDX-0159) (KIT receptor) Details Skin disease/disorder, Prurigo nodularis | Phase 2 Initiation | |
CDX-585 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CDX-1140 (CD40 agonist) Details Solid tumor/s, Cancer, Diffuse large B cell lymphoma | Failed Discontinued | |
CDX-527 (and PD-L1 / CD27) Details Solid tumor/s, Cancer | Failed Discontinued |